Imlifidase in Living Donor Renal Transplantation Highly Sensitized Recipients — LIVEDES  

Kidney Transplant Candidates Clinical Trial

Official title: Imlifidase in Living Donor Renal Transplantation Highly Sensitized Recipients (LIVEDES)

Status Not yet recruiting

Clinical Trial Summary

This is a Phase II, pilot, prospective, unicentric trial, to evaluate Imlifidase could improve the transplantability of the highly sensitized patients with good outcomes respect to survival and functionality of the graft.

Clinical Trial Description

The patients between 18 and 65 years will be flow cytometry crossmatch (FC-XM) positive against an available living donor. The imlifidase treatment will turn the crossmatch test negative prior to transplantation. A second dose of imlifidase can be given within 24 hours if the first dose is considered not to have sufficient effect. If a second dose is given, a confirmatory FCXM test will be performed pre-second imlifidase dosing and between 2-6 hours following the second dose. ;

Related Conditions & MeSH terms

• Kidney Transplant Candidates

• NCT number: NCT06461546
• Study type: Interventional
• Source: Fundacion Clinic per a la Recerca Biomédica
• Contact: Anna Cruceta, Phd
• Phone: +34 932275400
• Email: acruceta@recerca.clinic.cat
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: November 2024
• Completion date: December 2026